Clinical Trial Update: Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating autologous erythrocyte-derived MPs delivering methotrexate via peritoneal perfusion for malignant ascites.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Ascites

Drugs mentioned

• Autologous erythrocyte-derived MPs carrying methotrexate for peritoneal perfusion (methotrexate peritoneal perfusion via autologous erythrocyte-derived MPs)

Snippet

Sponsor: Hui ting Xu，MD | Conditions: Malignant Ascites | Phase 1, Phase 2 | Status: UNKNOWN